Plus and Harvard analysis shows CNSide enables early diagnosis and better clinical decision-making reducing healthcare costs ...

Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from ...

Patients received either BIIB122 or a placebo for 48 to 144 weeks.

The Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease did not meet its primary or secondary endpointsBased on data from the Phase 2b LUMA study, Biogen and Denali will discontinue deve ...

Studies published over the past year investigated Vielight’s itPBM technology across TBI, cognitive impairment, Long COVID-associated symptoms, athletic brain health, and cerebrospinal fluid dynamics ...

Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.

Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. I am Gaia Vasiliver-Shamis from LifeSci Advisors. Joining ...

eMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, ...

Abstract: Meningitis, a condition characterized by a serious inflammation of the meninges, necessitates timely diagnosis to get the best possible results for the patient. An examination of ...

Researchers at University of Tsukuba have found that cerebrospinal fluid (CSF) microdynamic motion shows region-specific alterations after mild traumatic brain injury (TBI). Using a specialized ...